University of Western Ontario

www.uwo.ca/
London, Canada

The University of Western Ontario , which is commonly referred to among Canadian universities as Western or Western University, is a public research university located in London, Ontario, Canada. The university was founded on 7 March 1878 by Bishop Isaac Hellmuth of the Anglican Diocese of Huron as "The Western University of London Ontario." It incorporated Huron University College, which had been founded in 1863. The first four faculties were Arts, Divinity, Law and Medicine. The Western University of London was eventually made non-denominational in 1908.According to the 2012 Academic Ranking of World Universities rankings, the university ranked 201–300 in the world and top 10 in Canada. The 2011 QS World University Rankings ranked the university 157th in the world, making it seventh in Canada. Several of Western's programs were also ranked in individual rankings. Social science at Western was ranked 96th in the world in the 2010 QS World University Rankings, and Western's Ivey Business School was ranked 1st in the World in the Global MBA Category of Bloomberg Businessweek.Western's Co-educational Student body of over 24,000 represents 107 countries around the world and Western scholars have established research and education collaborations and partnerships on every continent. There are more than 306,000 alumni who are active internationally, living and working around the globe. Notable alumni include government officials, academics, business leaders, Nobel Laureates, Rhodes Scholars, and distinguished fellows.Western's varsity teams, known as the Western Mustangs, compete in the Ontario University Athletics conference of the Canadian Interuniversity Sport. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Western Ontario | Date: 2017-08-02

A novel statherin-based fusion peptide is provided. The fusion peptide comprises the statherin peptide, DSSEEKFLR, or a functionally equivalent variant thereof, fused to an acquired enamel pellicle protein or peptide. The statherin-based fusion peptide is useful to treat dental demineralization. Also provided is hydrogel-encapsulated enamel-protective protein or peptides such as statherin, a statherin-based fusion peptide or a histatin.


Patent
University of Western Ontario | Date: 2017-01-25

Described herein is a head cooling system comprising: a source of compressed breathable gas; a vortex tube comprising an inlet, a hot gas outlet and a cold gas outlet, the inlet operably connected to the source of compressed breathable gas; and an interface for delivering cooled gas to a nasopharyngeal cavity in fluid communication with the cold gas outlet. The head cooling system may be used in a method to reduce neurodegeneration in a subject, for example neurodegeneration from ischemia, anoxia, cardiac arrest, trauma or neurodegenerative disease. The head cooling system may also be used in a method to prophylactically protect a subject at risk of neurodegeneration, for example neurodegeneration from ischemia, anoxia, cardiac arrest, trauma or neurodegenerative disease.


Patent
University of Western Ontario | Date: 2016-08-30

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31 C., and of poor replication or incapable of replication at about 37 C. or higher.


Patent
University of Western Ontario and Trudell Medical | Date: 2016-04-13

The present invention relates generally to an oral device, or mouthpiece, for delivering a fluid to the mouth or oropharynx of a user. In one embodiment, the oral device includes an intraoral portion, an extraoral portion, and an auxiliary support device that serves to stabilize the oral device. In various embodiments, the auxiliary support device may be configured with ear loops, a support band, a support frame and/or a support member. The intraoral portion generally includes at least one outlet port through which the fluid is delivered to the oral cavity or oropharynx. A method of dispensing a fluid using the oral device is also provided.


Patent
University of Western Ontario | Date: 2016-02-26

A method and system for hydrogen production from organic material such as waste. The system includes a bioreactor for continuous anerobic fermentation to produce hydrogen in which a mixture containing a microorganism and organic material is sonicated. The system optionally includes a biomethanator connected in-line with the bioreactor.


Patent
Trudell Medical and University of Western Ontario | Date: 2017-01-26

An oral appliance for use with a subject in his/her mouth includes a flexible tube having an input end and an output end and an electrode coupled to the flexible tube adjacent the output end. The flexible tube is adapted to be positioned in the subjects oral cavity with the output end positioned in a posterior region of the oral cavity. The electrode is adapted and configured to administer an electrical stimulation to the posterior region of the oral cavity. An electrode lead is disposed within the flexible tube and connected to the electrode. An electrical stimulation control unit is connected to the electrode lead. A method of administering an electrical stimulation to a posterior region of an oral cavity of a subject is also provided.


Patent
LANXESS Inc. and University of Western Ontario | Date: 2017-06-14

A polymer nanocomposite coating of an elastomeric film containing at least 30 wt% conductive nanoparticles based on combined weight of elastomer and conductive nanoparticles is provided. The conductive nanoparticles have an average particle size along each dimension of less than 500 nm for nanoparticles having an aspect ratio of less than 20:1 or have an average particle size along each dimension of less than 2000 nm for nanoparticles having an aspect ratio of 20:1 or greater. The conductive nanoparticles are formed into hierarchical micro- and nano-sized aggregates having re-entrant morphology. The coating is both superoleophobic and conductive and retains these properties even when stretched under strain to over 100%. The coatings may be produced with simple spray technology.


Patent
University of Western Ontario | Date: 2016-10-28

A method of processing a plurality of time separated images comprises selecting a plurality of imaging units in each image; measuring a temporal difference in each imaging unit; and selecting temporal differences above a threshold limit.


Patent
University of Western Ontario | Date: 2016-08-30

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31 C., and of poor replication or incapable of replication at about 37 C. or higher.


Patent
University of Western Ontario | Date: 2016-08-30

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31 C., and of poor replication or incapable of replication at about 37 C. or higher.

Loading University of Western Ontario collaborators
Loading University of Western Ontario collaborators